` EVG (Evgen Pharma PLC) vs FTSE All Share Index Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

EVG
vs
F
FTSE All Share Index

Over the past 12 months, EVG has underperformed FTSE All Share Index, delivering a return of 0% compared to the FTSE All Share Index's 0% growth.

Back to EVG Analysis

Stocks Performance
EVG vs FTSE All Share Index

Loading
EVG
FTSE All Share Index
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EVG vs FTSE All Share Index

Performance Gap Between EVG and ASX
HIDDEN
Show

Performance By Year
EVG vs FTSE All Share Index

Loading
EVG
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Evgen Pharma PLC vs Peers

FTSE All Share Index
EVG
RYI
AVGR
BROG
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Evgen Pharma PLC
Glance View

Market Cap
3.4m GBX
Industry
Biotechnology

Evgen Pharma Plc is a clinical stage drug development company, which engages in the development of pharmaceutical products and focus on cancer and neurological disease. The company is headquartered in Wilmslow, Cheshire and currently employs 8 full-time employees. The company went IPO on 2015-10-21. The firm is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The firm's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.

EVG Intrinsic Value
Not Available
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 319,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.